BMRA:NSD-Biomerica Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 3.06

Change

+0.24 (+8.51)%

Market Cap

USD 0.04B

Volume

0.02M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Biomerica Inc (BMRA) Stock Analysis:
Based on the Biomerica Inc stock forecasts from 0 analysts, the average analyst target price for Biomerica Inc is not available over the next 12 months. Biomerica Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Biomerica Inc is Very Bearish, which is based on 0 positive signals and 6 negative signals. At the last closing, Biomerica Inc’s stock price was USD 3.06. Biomerica Inc’s stock price has changed by -6.99% over the past week, -31.54% over the past month and -10.79% over the last year.

About

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-17 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
DXCM DexCom Inc

+7.56 (+2.33%)

USD32.85B 171.14 77.12
ALGN Align Technology Inc

+6.39 (+2.33%)

USD21.61B 30.87 18.18
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
PODD Insulet Corporation

+3.12 (+1.58%)

USD13.80B 829.42 84.91
ABMD Abiomed Inc

+4.44 (+1.75%)

USD11.56B 85.16 42.14
BRKR Bruker Corporation

+1.68 (+2.82%)

USD8.99B 33.27 17.75
SWAV ShockWave Medical Inc

+1.90 (+1.16%)

USD5.81B N/A 138.45
IART Integra LifeSciences Holdings ..

+2.62 (+4.39%)

USD4.93B 32.22 16.98
TNDM Tandem Diabetes Care Inc

+2.75 (+3.82%)

USD4.72B 307.71 186.72
IRTC iRhythm Technologies Inc

+0.07 (+0.05%)

USD3.93B N/A N/A

ETFs Containing BMRA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -21.34% 75% C 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.34% 75% C 46% F
Trailing 12 Months  
Capital Gain -15.24% 78% C+ 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.24% 78% C+ 52% F
Trailing 5 Years  
Capital Gain 14.18% 65% D 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.18% 65% D 48% F
Average Annual (5 Year Horizon)  
Capital Gain 27.20% 57% F 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.20% 57% F 79% C+
Risk Return Profile  
Volatility (Standard Deviation) 81.04% 35% F 17% F
Risk Adjusted Return 33.56% 54% F 61% D-
Market Capitalization 0.04B 25% F 15% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.56 33% F 23% F
Price / Cash Flow Ratio -7.37 70% C- 74% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -34.45% 46% F 29% F
Return on Invested Capital -55.76% 22% F 18% F
Return on Assets -14.25% 47% F 26% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 15.49 2% F 3% F
Short Percent 3.64% 52% F 44% F
Beta -0.68 98% A+ 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector